Items Tagged ‘alectinib’

September 21st, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


June 12th, 2017

Alecensa Superior to Xalkori in Treatment of Lung Cancer

By

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small cell lung cancer (NSCLC) in […]

View full entry

Tags: Alecensa, alectinib, ALK gene, ALK-positive NSCLC, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, xalkori


December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

By

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc


December 3rd, 2015

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer

By

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication article in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer-related deaths in the United States. Non-small cell lung […]

View full entry

Tags: alectinib, alk, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell


September 15th, 2015

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Xalkori™ (crizotinib).  Alectinib was previously granted Breakthrough Therapy Designation by the FDA for people with ALK-positive […]

View full entry

Tags: alectinib, ALK inhibitor, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV